Real-World Evidence

Targeted Literature Review Of Economic Burden And Modelling Techniques For Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are rare X-linked recessive ailments impacting 1 in 7,250 people in the United States (U.S.). Currently, DMD has no known cure. Disease management is aimed at preserving the quality of life and extending survival. The objective of this study is to assess economic burden, current economic evaluation techniques, and data sources for DMD economic evaluation and identify evidence gaps in DMD burden and provide details on the value of existing DMD treatments.

Contact us at connect@axtria.com with any questions.

Complete the brief form to download the white paper

Recommended insights

Economic Burden & Modelling Techniques Report

Case Study

Long-Term Partnership Helps Advance Real World Evidence in Regulatory and Clinical Decision-Making
Economic Burden & Modelling Techniques Report

White Paper

Digital Twins: A Fit-for-Purpose Solution to Elevate Clinical Trial Power and Efficiency
Economic Burden & Modelling Techniques Report

Article

Evidence at the Forefront: Why Integrated Evidence Planning is Essential for Biopharma Innovation